Atlas
Glucose & insulin

Glycated hemoglobinHbA1c

Integrated glycemia over the prior 8–12 weeks; the diagnostic and monitoring workhorse.

Sample
EDTA whole blood
Fasting
Not required
Clinical reference range
to 5.6 %
Normal
Conv: 5.6 %Func: 4.65.3 %
Biology

What it measures

Non-enzymatic glycation of valine on the β-chain of hemoglobin. Concentration reflects mean glucose weighted toward the most recent month (50% from last 30 d).

Clinical use

Why we order it

Diagnose diabetes (≥6.5%), set treatment targets, and monitor therapy. Avoids fasting and within-day variation.

Lens · Clinical

Interpretation by lens

Clinical interpretation

ADA target <7% for most adults; <6.5% if achievable without hypoglycemia; <8% in frail elderly or limited life expectancy.

Functional interpretation

Functional 'optimal' 4.6–5.3% is a long-term metabolic target; values 5.4–5.7 already correlate with insulin resistance in many cohorts.

Research note

HbA1c–glucose discordance (high glycation index) is independently associated with microvascular complications.

Differential

Causes of abnormal values

Causes of HIGH
  • Hyperglycemia
  • Iron deficiency anemia (falsely raises A1c)
  • Splenectomy / decreased RBC turnover
  • Uremia (carbamylation interferes with some assays)
Causes of LOW
  • Hemolysis
  • Recent transfusion
  • Pregnancy (lower turnover)
  • Hemoglobinopathies (HbS, HbC) — verify with A1c assay validation
Pitfalls

Pre-analytic & interpretation traps

  • !HbA1c is unreliable in any condition that alters RBC lifespan — use fructosamine or CGM-derived measures instead.
  • !African ancestry HbS or HbC trait can interfere with some assays — request electrophoresis if A1c discordant with glucose.
Follow-up orders

Logical next-step labs

Evidence-graded claims

What the data says

A
HbA1c ≥6.5% diagnoses diabetes when assay is standardized
ADA, IDF, WHO.
A
Tight glycemic control (<7%) reduces microvascular complications in type 2
UKPDS.
D
Aggressive A1c targets (<6.5%) reduce macrovascular risk
ACCORD found increased mortality with aggressive glycemic targets.
References

Primary literature

Related

Related biomarkers